Genetic Signatures: From $4.9m to $28m in annual revenues in just 3 years 

Listen to ASX-listed Genetic Signatures CEO Dr John Melki talk to Matt Birney on the Bulls N’ Bears Report about Genetic Signatures’ remarkable hike in revenue from its test kit that can detect infectious diseases – including COVID-19.

Genetic Signatures: From $4.9m to $28m in annual revenues in just 3 years 
Listen to ASX-listed Genetic Signatures CEO Dr John Melki talk to Matt Birney on the Bulls N&rsquo; Bears Report about Genetic Signatures&rsquo; remarkable hike in revenue from its test kit that can detect infectious diseases &ndash; including COVID-19.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N’ Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia’s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N&rsquo; Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia&rsquo;s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Advertisement